Northwest Biotherapeutics reported $82.97M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Celldex Therapeutics USD 60.52M 808K Sep/2026
Eisai JPY 393.64B 53.39B Jun/2026
Merck USD 28.8B 1.07B Sep/2026
Northwest Biotherapeutics USD 82.97M 4.93M Mar/2026
Pfizer USD 31.73B 920M Sep/2026
Plus Therapeutics USD 8.57M 612K Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026